Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer

Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer

Shots:

  • The P-III KEYNOTE-522 study involves assessing of Keytruda + CT vs PBO + CT as neoadjuvant therapy, followed Keytruda vs PBO as adjuvant therapy in 1,174 patients in a ratio (2:1) with TNBC
  • The P-III KEYNOTE-522 study resulted in meeting its one of the dual 1EPs i.e, improvement in pCR rates regardless of PD-L1 status, safe and tolerable, no new safety signals were observed
  •  Keytruda is an anti-PD-1 therapy, blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activated T-lymphocytes affecting both tumor and healthy cells, being evaluated in three ongoing studies for TNBC (KEYNOTE-355, KEYNOTE-242 and KEYNOTE-522)

Click here to­ read full press release/ article | Ref: Merck | Image: LinkedIn